Herbal composition PC-SPES for management prostate cancer: Identification of active principles

Journal of the National Cancer Institute

Volumn 94, Issue 17, 2002, Pages 1275-1281

  Sovak, Milos ^a,i   Seligson, Allen L ^b   Konas, Martin ^c   Hajduch, Marian ^d   Dolezal, Marek ^e   Machala, Miroslav ^f   Nagourney, Robert ^g,h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Biophysica Research   (United States)

^c Interpharma Praha ^*  (Czech Republic)

^d PALACKÝ UNIVERSITY   (Czech Republic)

^e INSTITUTE OF CHEMICAL TECHNOLOGY   (Czech Republic)

^f VETERINARY RESEARCH INSTITUTE   (Czech Republic)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h Rational Therapeutics   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAICALIN; D 4628; DIETHYLSTILBESTROL; I 7378; INDOMETACIN; LICOCHALCONE A; NATURAL PRODUCT; PC SPES; PHYTOSTEROL; S 2424; S 9889; WARFARIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; BREAST CANCER; CANCER CELL CULTURE; CHEMICAL COMPOSITION; COLONY FORMATION; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG ISOLATION; DRUG MANUFACTURE; DRUG QUALITY; GAS CHROMATOGRAPHY; GOOD MANUFACTURING PRACTICE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; MALE; MASS SPECTROMETRY; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY CONTROL; REPORTER GENE; THROMBOEMBOLISM;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICOAGULANTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLONY-FORMING UNITS ASSAY; DIETHYLSTILBESTROL; DRUGS, CHINESE HERBAL; ESTROGEN RECEPTOR ALPHA; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; INDOMETHACIN; MALE; NEOPLASMS, HORMONE-DEPENDENT; PHYTOSTEROLS; PLANT EXTRACTS; PROSTATIC NEOPLASMS; RECEPTORS, ESTROGEN; TUMOR CELLS, CULTURED; WARFARIN;

EID: 0037019735     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Small EJ, Frohlich MW, Bok R, Shinohara K, Grossfeld G, Rozenblat Z, et al. Prospective trial of the herbal supplement PC-SPES in patients with progressive prostate cancer. J Clin Oncol 2000;18:3595-603.
2. de la Taille A, Buttyan R, Hayek O, Bagiella E, Shabsigh A, Burchardt M, et al. Herbal therapy PC-SPES: in vitro effects and evaluation of its efficacy in 69 patients with prostate cancer. J Urol 2000;164:1229-34.
3. DiPaola RS, Zhang H, Lambert GH, Meeker R, Licitra E, Rafi MM, et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 1998;339:785-91.
4. Geliebter J, Mittelman A, Tiwari RK. PC-SPES and prostate cancer. J Nutr 2001;131:164S-6S.
5. Darzynkiewicz Z, Traganos F, Wu JM, Chen S. Chinese herbal mixture PC SPES in treatment of prostate cancer. Int J Oncol 2000;17:729-36.
6. Tiwari RK, Geliebter J, Garikapaty VP, Yedavelli SP, Chen S, Mittelman A. Anti-tumor effects of PC-SPES, an herbal formulation in prostate cancer. Int J Oncol 1999;14:713-9.
7. Ikezoe T, Chen SS, Heber D, Taguchi H, Koeffler HP. Baicalin is a major component of PC-SPES which inhibits the proliferation of human cancer cells via apoptosis and cell cycle arrest. Prostate 2001;49:285-92.
8. Rafi MM, Rosen RT, Vassil A, Ho CT, Zhang H, Ghai G, et al. Modulation of bcl-2 and cytotoxicity by licochalcone-A, a novel estrogenic flavonoid. Anticancer Res 2000;20:2653-8.
9. Agricultural Research Service (ARS). Dr. Duke's Phytochemical and Ethnobotanical Databases. U.S. Department of Agriculture-ARS-National Germplasm Resources Laboratory (NGRL), Beltsville, Maryland. [Last accessed: 7/19/02]. Available at: http://www.ars-grin.gov/cgi-bin/duke/farmacy2.pl?507.
10. Weinrobe MC, Montgomery B. Acquired bleeding diathesis in a patient taking PC-SPES. N Engl J Med 2001;345:1213-4.
11. Islam A, Hossain MA. Synthesis of licochalcone A. Indian J Chem 1993;32B:713-5.
12. 1H FT-NMR Spectra. Vol 2. 1st ed. 1993. p. 332.
13. International Union of Pure and Applied Chemistry, Applied Chemistry Division, Commission on Oils, Fat and Derivatives. Standard methods for the analysis of oils, fats, and derivatives. 7th revised and enlarged edition. Determination of the total sterols content. Prepared for publication by Paquot C, Hautfenne A. Oxford (UK): Blackwell Scientific Publications; 1987. p. 170-3.
14. Cemazar M, Marolt D, Lavric M, et al. Comparison of colorimetric MTT and clonogenic assays for irradiation and cisplatin treatment on murine fibrosarcoma SA-1 cells. Radiol Oncol 1999;33:303-8.
15. Demirpence E, Duschesne MJ, Badia E, Gagne D, Pons M. MVLN cells: a bioluminescent MCF-7-derived cell line to study the modulation of estrogenic activity. J Steroid Biochem Mol Biol 1993;46:355-64.
16. Liu J, Burdette JE, Xu H, Gu C, van Breemen RB, Bhat KP, et al. Evaluation of estrogenic activity of plant extracts for the potential treatment of menopausal symptoms. J Agric Food Chem 2001;49:2472-9.
17. Pirani JF. The effects of phytotherapeutic agents on prostate cancer: an overview of recent clinical trials of PC SPES. Urology 2001;58:36-8.
18. Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ. A phase II trial of oral diethylstilbestrol as a second-line hormonal agent in advanced prostate cancer. Urology 1998;52:257-60.
19. Rosenbaum E, Wygoda M, Gips M, et al. Diethylstilbestrol is an active agent in prostatic cancer patients after failure to complete androgen blockade (abstract 1372). Proc ASCO 2000:19.
20. Cox RL, Crawford ED. Estrogens in the treatment of prostate cancer. J Urol 1995;154:1991-8.
21. Malkowicz SB. The role of diethylstilbestrol in the treatment of prostate cancer. Urology 2001;58:108-13.
22. Byar DP. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 1973;32: 1126-30.
23. Byar DP, Corle DK. Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr 1988;(7):165-70.
24. Geller J. Megestrol acetate plus low-dose estrogen in the management of advanced prostatic carcinoma. Urol Clin North Am 1991;18:83-91.
25. Small EJ, Kantoff PW, Weinberg VK, Nguyen S, Smith M, Bubley GJ, et al. A prospective multicenter randomized trial of the herbal supplement, PC-SPES vs. diethylstilbestrol (DES) in patients with advanced, androgen independent prostate cancer (AiPCa). Proc ASCO 2002; 21:178a.
26. Robertson CN, Roberson KM, Padilla GM, O'Brien ET, Cook JM, Kim CS, et al. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst 1996;88:908-17.
27. Kitahara S, Umeda H, Yano H. Effects of intravenous administration of high dose diethylstilbestrol diphosphate on serum hormonal levels in patients with hormone-refractory prostate cancer. Endocr J 1999;46: 659-64.
28. Lerner EJ, Carminati P, Schiatti P. Correlation of anti-inflammatory activity with inhibition of prostaglandin synthesis activity of nonsteroidal anti-estrogens and estrogens (38532). Proc Soc Exp Biol Med 1975;148: 329-32.
29. Sawaoka H, Kawano S, Tsuji S, Tsujii M, Gunawan ES, Takei Y, et al. Cyclooxygenase-2 inhibitors suppress the growth of gastric cancer xenografts via induction of apoptosis in nude mice. Am J Physiol 1998;274: G1061-7.
30. Galasko CS, Rawlins R, Bennett A. Timing of indomethacin in the control of prostaglandins, osteoclasts and bone destruction produced by VX2 carcinoma in rabbits. Br J Cancer 1979;40:360-4.
31. Duffy CP, Elliott CJ, O'Connor RA, Heenan MM, Coyle S, Cleary IM, et al. Enhancement of chemotherapeutic drug toxicity to human tumour cells in vitro by a subset of non-steroidal anti-inflammatory drugs (NSAIDs). Eur J Cancer 1998;34:1250-9.